BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting
Nov 05, 2020 9:00 AM
Oral Presentation:
Title: |
Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial |
|
Publication #: |
339 |
|
Session Title: |
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Clinical studies in Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma and Hairy Cell Leukemia |
|
Date and Time: |
|
|
Presenter: |
|
Poster Presentations:
Title: |
Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial |
|
Publication #: |
2940 |
|
Session Title: |
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III |
|
Date: |
|
|
Presenter: |
Gang An, M.D., Ph.D., |
Title: |
Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib |
|
Publication #: |
2947 |
|
Session Title: |
623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III |
|
Date: |
|
|
Presenter: |
|
Title: |
Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial |
|
Publication #: |
1306 |
|
Session Title: |
642. CLL: Therapy, excluding Transplantation: Poster I |
|
Date: |
|
|
Presenter: |
|
Title:
|
Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action |
|
Publication #: |
1116 |
|
Session Title: |
622. Lymphoma Biology—Non-Genetic Studies: Poster I |
|
Date: |
|
|
Presenter: |
|
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20201105005064/en/
Investor Contact
+1 857-302-5189
ir@beigene.com
Media Contact
+1 857-302-5663 or +1 857-302-7596
media@beigene.com
Source: